FibroBiologics, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| – | – | – | – | – | – | |
| – | – | – | +364.9% | +31.1% | +45.2% | |
| – | – | – | +566.0% | +25.7% | +21.0% | |
| – | – | +78.5% | +60.6% | +13.4% | -692.5% | |
| – | – | – | – | -62.8% | +42.4% | |
| – | – | – | – | -62.8% | +42.4% | |
| – | – | +147.5% | -92.1% | +3,033.3% | -89.6% | |
| – | +55.4% | +226.1% | +132.8% | +22.6% | -55.3% | |
| – | – | +356.8% | +271.0% | -30.1% | -288.5% | |
| – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.